SFDA Launches ‘Traveler’s Permit for Controlled Drugs’ Service at LEAP25

The Saudi Food and Drug Authority (SFDA) launched the ‘Traveler’s Permit for Controlled Drugs’ service at the LEAP25 technology conference in Riyadh. The service, introduced by SFDA CEO Dr. Hisham Aljadhey on February 13, 2025, streamlines the entry and exit process for travelers carrying controlled medications, enhancing both convenience and regulatory oversight.

Context and Background

The new service addresses the dual need of facilitating travel for individuals requiring controlled medications for medical conditions while ensuring compliance with Saudi Arabia’s stringent drug control regulations. By digitizing the permit process through the existing Electronic Controlled Drugs System (CDS), the SFDA aligns with the Kingdom’s broader digital transformation goals under Vision 2030.

Key Details

Travelers arriving or departing from Saudi Arabia can declare their controlled medications in advance via the CDS portal at https://cds.sfda.gov.sa/. The online application requires details on the type and quantity of medication, duration of stay, and supporting documentation. The system reviews applications per established procedures and issues permits that travelers can present to authorities at ports of entry and during their stay. The service strengthens monitoring alongside other government agencies to prevent misuse and ensure adherence to international regulations.

Implications and Impact

This initiative simplifies medical travel to Saudi Arabia, supporting the tourism sector by reducing bureaucratic hurdles. It also contributes to public health safety by restricting controlled drugs to authorized individuals. The service is expected to boost the country’s attractiveness as a global tourist and business destination, facilitating smoother travel for millions of visitors.

Vision 2030 Alignment

The Traveler’s Permit service directly supports Vision 2030 by modernizing regulatory processes and enhancing the quality of life for residents and visitors. By leveraging digital technology, the SFDA reinforces Saudi Arabia’s commitment to efficient, transparent governance and positions the Kingdom as a leading hub for tourism and innovation.

20 Questions

Q1. What is the ‘Traveler’s Permit for Controlled Drugs’ service?

A1. It is a digital service launched by the SFDA that allows travelers to declare and obtain permits for carrying controlled medications when entering or leaving Saudi Arabia.

Q2. Who launched the service and when?

A2. The service was launched by SFDA CEO Dr. Hisham Aljadhey at the LEAP25 conference in Riyadh on February 13, 2025.

Q3. What is the purpose of this service?

A3. The service aims to enhance travel convenience for individuals needing controlled medications while ensuring appropriate oversight and compliance with regulations.

Q4. How can travelers apply for the permit?

A4. Travelers can apply online through the Electronic Controlled Drugs System (CDS) at https://cds.sfda.gov.sa/ by submitting required documentation.

Q5. What information is required in the application?

A5. The application requires details on the type and quantity of medication, duration of stay, and supporting documents.

Q6. How are applications reviewed?

A6. Applications are reviewed and processed according to established procedures set by the SFDA.

Q7. What happens after a permit is approved?

A7. Travelers receive a permit that can be presented to relevant authorities at ports of entry and during their stay in the Kingdom.

Q8. How does this service improve oversight of controlled drugs?

A8. It ensures monitoring and prevents misuse by restricting transport to authorized individuals or their designated representatives.

Q9. Does the service collaborate with other government agencies?

A9. Yes, it works with relevant government authorities to strengthen oversight and ensure adherence to local and international regulations.

Q10. How does the service benefit travelers?

A10. It simplifies the declaration process, creating a transparent and efficient experience for entry, stay, and departure.

Q11. Who can use the service?

A11. Travelers arriving in or departing from Saudi Arabia who require controlled medications for medical conditions can use the service.

Q12. Is the service available to non-Saudi travelers?

A12. Yes, the service is open to all travelers, including international visitors and residents of Saudi Arabia.

Q13. What types of medications are considered controlled drugs?

A13. Controlled drugs are substances regulated under Saudi law due to their potential for abuse or medical necessity, such as certain painkillers and psychotropics.

Q14. How does this support Saudi Vision 2030?

A14. It aligns with Vision 2030 by digitizing regulatory processes, enhancing tourism, and improving quality of life through efficient services.

Q15. What is the role of the Electronic Controlled Drugs System?

A15. The CDS is the online platform that processes applications and issues permits for controlled medications, ensuring secure and efficient management.

Q16. Why was the service launched at LEAP25?

A16. LEAP25 is a major technology conference, highlighting the service as part of Saudi Arabia’s digital transformation and innovation in governance.

Q17. How does the service prevent drug misuse?

A17. By requiring advance declaration and approval, it ensures only authorized individuals carry controlled drugs, reducing opportunities for misuse.

Q18. What should travelers do if their application is denied?

A18. Travelers should contact the SFDA for guidance on meeting requirements or alternative arrangements, as procedures ensure compliance.

Q19. How does the service affect tourism in Saudi Arabia?

A19. It reduces bureaucratic hurdles for medical travelers, making Saudi Arabia more attractive as a tourist destination and supporting the tourism sector.

Q20. Who can travelers contact for more information?

A20. Travelers can visit the SFDA website or contact their customer service for detailed guidance on the permit process.

---